

Orsiro™ Mission™

Drug-Eluting Stent (DES)

The Orsiro™ Mission™ Sirolimus-Eluting Coronary Stent System is a drug-eluting balloon-expandable stent pre-mounted on a rapid-exchange PTCA catheter delivery system.

Indication

Orsiro™ Mission™ DES is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions (length ≤40 mm) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm including the following patient and lesion subsets:

- Acute Coronary Syndrome (ACS)
- ST-Elevation Myocardial Infarction (STEMI)
- Diabetes Mellitus (DM)
- High Bleeding Risk (HBR)
- One month of Dual Antiplatelet Therapy (DAPT) in HBR patients
- Calcified lesions (moderate/severe calcification)
- Complex Lesions (B2/C)
- Long Lesions (LL) (e.g. ≥20 mm)
- Small Vessels (SV) (e.g. ≤2.75 mm)
- Multi-Vessel Disease (MVD)
- Male/Female
- Old Patients (e.g. >65 y)

Vascular
Intervention
Coronary



Technical Data

| STENT | |
|----------------------------|---|
| Stent material | Cobalt chromium, L-605 |
| Strut thickness | ∅ 2.25–3.0 mm: 60 µm (0.0024"); ∅ 3.50–4.0 mm: 80 µm (0.0031") |
| Passive coating | proBIO™ (Amorphous Silicon Carbide) |
| Active coating | BIOlute™ bioabsorbable Poly-L-Lactide (PLLA) eluting a limus drug |
| Drug dose | 1.4 µg/mm ² |
| DELIVERY SYSTEM | |
| Catheter type | Rapid exchange |
| Recommended guide catheter | 5F (min. I.D. 0.056") |
| Guide wire diameter | 0.014" |
| Usable catheter length | 140 cm |
| Balloon material | Semi crystalline polymer material |
| Coating (Distal shaft) | Hydrophilic |
| Coating (Proximal shaft) | Hydrophobic |
| Marker bands | Two swaged platinum-iridium markers |
| Lesion entry profile | 0.017" |
| Distal shaft diameter | 2.7F: ∅ 2.25–3.0 mm; 2.9F: ∅ 3.5–4.0 mm |
| Proximal shaft diameter | 2.0F |
| Nominal pressure (NP) | 10 atm |
| Rated burst pressure (RBP) | 16 atm |
| STORAGE | |
| Use Before Date (UBD) | 36 months |
| Temperature | Between 15°C (59°F) and 25°C (77°F), short term excursions between 10°C (50°F) and 40°C (104°F) are allowed |

Double helix stent design


| NOMINAL DIAMETER | 2.25 MM | 2.5 MM | 2.75 MM | 3.0 MM | 3.5 MM | 4.0 MM |
|-------------------------|---------|--------|---------|--------|--------|--------|
| Strut thickness | 60 µm | | | | 80 µm | |
| Strut width | 75 µm | | | | 85 µm | |
| Amount of connectors | | | | | 3 | |
| Amount of crowns at end | | | | | 8 | |

Maximal expansion and stent strut opening

| NOMINAL DIAMETER | 2.25 MM | 2.5 MM | 2.75 MM | 3.0 MM | 3.5 MM | 4.0 MM |
|---|---------|---------|---------|---------|---------|---------|
| Nominal outer diameter of the stent at NP | 2.37 mm | 2.62 mm | 2.87 mm | 3.12 mm | 3.66 mm | 4.16 mm |
| Maximal expansion diameter | 4.0 mm | | | | 5.0 mm | |
| Stent strut opening diameter at NP* | 0.79 mm | 0.92 mm | | | 1.06 mm | 1.25 mm |
| Maximal diameter of expanded stent cell | 3.59 mm | | | | 4.42 mm | |

*Mean of the largest possible opening diameter within a stent cell at NP

Product schematic representation



Ordering information

| STENT Ø | STENT LENGTH | | | | | | | | |
|---------|--------------|--------|--------|--------|--------|--------|--------|--------|--------|
| | 9 mm | 13 mm | 15 mm | 18 mm | 22 mm | 26 mm | 30 mm | 35 mm | 40 mm |
| 2.25 mm | 419101 | 419107 | 419113 | 419119 | 419125 | 419131 | 419137 | 419143 | 419149 |
| 2.50 mm | 419102 | 419108 | 419114 | 419120 | 419126 | 419132 | 419138 | 419144 | 419150 |
| 2.75 mm | 419103 | 419109 | 419115 | 419121 | 419127 | 419133 | 419139 | 419145 | 419151 |
| 3.00 mm | 419104 | 419110 | 419116 | 419122 | 419128 | 419134 | 419140 | 419146 | 419152 |
| 3.50 mm | 419105 | 419111 | 419117 | 419123 | 419129 | 419135 | 419141 | 419147 | 419153 |
| 4.00 mm | 419106 | 419112 | 419118 | 419124 | 419130 | 419136 | 419142 | 419148 | 419154 |

Teleflex, the Teleflex logo, BIOlute, Orsiro, Orsiro Mission, and proBIO are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries.

Please refer to the IFU for indications and post-procedure antiplatelet therapy recommendations applying in your country. Please contact your local representative.
Revised: 11/2025.

© 2025 Teleflex Incorporated. All rights reserved.

Distributed by:

Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com
United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com
South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

teleflex.com

Teleflex[™]
Empowering the future of healthcare